Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.

[1]  A. Hart,et al.  Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment , 2021, Alimentary pharmacology & therapeutics.

[2]  S. Ng,et al.  International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease , 2021, Nature Reviews Gastroenterology & Hepatology.

[3]  T. Pietrzykowski,et al.  The reality of informed consent: empirical studies on patient comprehension—systematic review , 2021, Trials.

[4]  G. Rogler,et al.  Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program , 2020, Inflammatory bowel diseases.

[5]  B. Sands,et al.  Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  B. Sands,et al.  Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme , 2019, Alimentary pharmacology & therapeutics.

[7]  H. Yazici,et al.  Informed consent: time for more transparency , 2010, Arthritis research & therapy.

[8]  A. Iliadou,et al.  Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[9]  E. Zintzaras,et al.  The risk of lymphoma development in autoimmune diseases: a meta-analysis. , 2005, Archives of internal medicine.

[10]  C. Brensinger,et al.  Inflammatory bowel disease is not associated with an increased risk of lymphoma. , 2001, Gastroenterology.

[11]  Daryl E. Chubin,et al.  Open Science and Closed Science: Tradeoffs in a Democracy , 1985 .